Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Official Title

A Phase 1 Study Of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, In Combination With Chemotherapy In Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Or Lymphoblastic Lymphoma (LL)

Brief Summary

      AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a
      standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and
      lymphoblastic lymphoma (LL). LL patients are included because the patient population is rare
      and these patients are most commonly treated with ALL regimens. The proposed palbociclib
      starting dose for this study will be 50 mg/m^2/day for 21 days.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of
      palbociclib administered in combination with re-induction chemotherapy in pediatric patients
      with relapsed B- or T-lineage ALL/LL.

      II. To define and describe the toxicities of palbociclib administered on this schedule.

      III. To characterize the pharmacokinetics of palbociclib in pediatric patients with relapsed
      B- or T-lineage ALL/LL.

      SECONDARY OBJECTIVES:

      I. To preliminarily define the antitumor activity of palbociclib in combination with
      chemotherapy for children with relapsed ALL/LL within the confines of a Phase 1 study.

      II. To assess the biologic activity of palbociclib in this patient population.

      OUTLINE:

      Patients receive Palbociclib PO (or via NG-tube) once daily on Days 1-21; Intrathecal
      cytarabine (IT ARAC) on Day 1, Doxorubicin IV push or infusion over 1-15 min on Day 4;
      Prednisone or prednisolone PO on days 4-31; Vincristine IV push or mini-bag per institutional
      policy on Days 4, 11, 18, and 25; and Pegaspargase IV over 1-2 hours on Days 5, and 18. If
      CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) on days 4, 11,18,
      and 25. If CNS1 or 2 disease status, patients receive Methotrexate (IT MTX) on Days 18 and
      32. Patients known to be CNS3 at study entry may receive ITT on Day 1 rather than IT ARAC.
      Treatment will be given for one cycle, 32 days, in the absence of disease progression or
      unacceptable toxicity.
    

Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Frequency of dose limiting toxicities of Palbociclib

Secondary Outcome

 Antitumor effect of Palbociclib

Condition

Leukemia, Lymphocytic

Intervention

Palbociclib

Study Arms / Comparison Groups

 Treatment (Palbociclib)
Description:  Patients receive Palbociclib 50 mg/m^2 (starting dose with maximum dose of 100 mg) PO (or via NG-tube) once daily on Days 1-21; Intrathecal cytarabine (IT ARAC) age-based dosing on Day 1, Doxorubicin 60 mg/m^2 IV push or infusion over 1-15 min on Day 4; Prednisone or prednisolone 40 mg/m^2 PO divided BID or TID on days 4-31; Vincristine 1.5 mg/m^2 (maximum dose 2 mg) IV push or mini-bag per institutional policy on days 4, 11, 18, and 25; and Pegaspargase 2500 IU/m^2 IV over 1-2 hours on Days 5, and 18. If CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) age-based dosing on days 4, 11, 18, and 25. Patients known to be CNS3 at study entry may receive ITT on Day 1 rather than IT ARAC. If CNS1 and 2 leukemia present, patient receive Methotrexate (IT MTX) age-based dosing on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

15

Start Date

April 11, 2019

Completion Date

December 31, 2021

Primary Completion Date

December 31, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with recurrent or refractory B- or T-lineage lymphoblastic leukemia and
             lymphoma.

          -  Patients with leukemia must have ≥ 5% (M2 or M3) bone marrow blasts with or without an
             extramedullary site of relapse. Morphologic relapse for M2 should be confirmed using
             flow cytometry, FISH and/or cytogenetics or molecular techniques.

          -  Patients with LL must have either measurable or evaluable disease.

          -  Patients with first or greater relapsed T-lineage ALL or LL and second or greater
             relapsed B-lineage ALL or LL are eligible.

          -  Patients with primary refractory disease with at least 2 prior induction attempts or
             first relapse refractory to at least one prior re-induction attempt are eligible.

          -  Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients <= 16
             years of age.

               -  Note: Patients who are unable to walk because of paralysis, but who are up in a
                  wheelchair, will be considered ambulatory for the purpose of assessing the
                  performance score.

          -  Patients must have fully recovered from the acute toxic effects of all prior
             anti-cancer therapy and must meet the following minimum duration from prior
             anti-cancer directed therapy prior to enrollment. If after the required timeframe, the
             numerical eligibility criteria are met, e.g., blood count criteria, the patient is
             considered to have recovered adequately.

               1. Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive.
                  See DVL homepage for commercial and Phase 1 investigational agent
                  classifications. For agents not listed, the duration of this interval must be
                  discussed with the study chair and the study-assigned Research Coordinator prior
                  to enrollment.

                    -  A waiting period prior to enrollment is not required for patients receiving
                       standard cytotoxic maintenance chemotherapy (i.e., corticosteroid,
                       vincristine, 6MP, and/or methotrexate).

                    -  Intrathecal cytotoxic therapy: No waiting period is required for patients
                       having received intrathecal cytarabine, methotrexate, and/or hydrocortisone.
                       Intrathecal chemotherapy given at the time of diagnostic LP to evaluate for
                       relapse prior to study enrollment is allowed.

                         -  14 days must have elapsed after the completion of other cytotoxic
                            therapy, with the exception of hydroxyurea, for patients not receiving
                            standard maintenance therapy. Additionally, patients must have fully
                            recovered from all acute toxic effects of prior therapy.

                              -  NOTE: Cytoreduction with hydroxyurea in patients can be initiated
                                 and continued for up to 24 hours prior to the start of protocol
                                 therapy.

                              -  Note: Intrathecal chemotherapy that is given up to 72 hours prior
                                 to initiation of systemic chemotherapy per AINV18P1 counts as
                                 protocol therapy and not prior anti-cancer therapy. Intrathecal
                                 chemotherapy given > 72 hours prior does not count as protocol
                                 therapy.

               2. Anti-cancer agents not known to be myelosuppressive (e.g. not associated with
                  reduced platelet or ANC counts): >= 7 days after the last dose of agent. See DVL
                  homepage for commercial and Phase 1 investigational agent classifications. For
                  agents not listed, the duration of this interval must be discussed with the study
                  chair and the study-assigned Research Coordinator prior to enrollment.

                    -  NOTE: Cytoreduction with prednisone or methylprednisolone for <= 120 hours
                       (5 days) in patients can be initiated and continued for up to 24 hours prior
                       to the start of protocol therapy.

               3. Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody
                  with the exception of blinatumomab, and toxicity related to prior antibody
                  therapy must be recovered to Grade <= 1. Patients must have been off blinatumomab
                  infusion for at least 14 days and all drug related toxicity must have resolved to
                  Grade <= 1.

               4. Corticosteroids: If used to modify immune adverse events related to prior
                  therapy, >= 14 days must have elapsed since last dose of corticosteroid and
                  toxicity related to prior immune therapy must be recovered to Grade <= 1 off
                  corticosteroids.

               5. Hematopoietic growth factors: >= 14 days after the last dose of a long-acting
                  growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor. For
                  agents that have known adverse events occurring beyond 7 days after
                  administration, this period must be extended beyond the time during which adverse
                  events are known to occur. The duration of this interval must be discussed with
                  the study chair and the study-assigned Research Coordinator.

               6. Interleukins, Interferons and Cytokines (other than Hematopoietic Growth
                  Factors): >= 21 days after the completion of interleukins, interferon or
                  cytokines (other than Hematopoietic Growth Factors)

               7. Stem cell Infusions (with or without TBI):

                    -  Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem
                       cell infusion including DLI or boost infusion: >= 84 days after infusion and
                       no evidence of GVHD.

                    -  Autologous stem cell infusion including boost infusion: >= 42 days.

               8. Cellular Therapy: >= 30 days after the completion of any type of cellular therapy
                  (e.g. modified T cells, NK cells, dendritic cells, etc.)

               9. XRT/External Beam Irradiation including Protons: >= 14 days after local XRT; >=
                  150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >=
                  42 days if other substantial BM radiation.

              10. Patients must not have received prior exposure to palbociclib or another CDK4/6
                  inhibitor.

          -  Adequate Renal Function Defined as:

               -  Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or

               -  A serum creatinine based on age/gender as follows:

                    -  Age: 1 to < 2 years; Male: 0.6 mg/dL; Female: 0.6 mg/dL

                    -  Age: 2 to < 6 years; Male: 0.8 mg/dL; Female: 0.8 mg/dL

                    -  Age: 6 to < 10 years; Male: 1 mg/dL; Female: 1 mg/dL

                    -  Age: 10 to < 13 years; Male: 1.2 mg/dL; Female: 1.2 mg/dL

                    -  Age: 13 to < 16 years; Male: 1.5 mg/dL; Female: 1.4 mg/dL

                    -  Age: >= 16 years; Male: 1.7 mg/dL; Female: 1.4 mg/dL

          -  Adequate Liver Function Defined as:

               -  bilirubin (sum of conjugated + unconjugated) <= 1.5 x upper limit of normal (ULN)
                  for age

               -  SGPT (ALT) <= 225 U/L unless disease-related. For the purpose of this study, the
                  ULN for SGPT is 45 U/L.

               -  Serum albumin >= 2 g/dL.

          -  Adequate Cardiac Function Defined As:

               -  Shortening fraction of >= 27% by echocardiogram, or

               -  Ejection fraction of >= 50% by gated radionuclide study.

          -  All patients and/or their parents or legally authorized representatives must sign a
             written informed consent. Assent, when appropriate, will be obtained according to
             institutional guidelines.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women will not be entered on this study due to risks of
             fetal and teratogenic adverse events as seen in animal/human studies. Based on the
             mechanism of action, palbociclib may be expected to cause fetal harm if used during
             pregnancy. Pregnancy tests must be obtained in girls who are post-menarche. Males or
             females of reproductive potential may not participate unless they have agreed to use
             an effective contraceptive method for the duration of study therapy. Women of
             reproductive potential should use effective contraception during treatment and for at
             least 3 weeks after the last dose of palbociclib. Males with female partners of
             reproductive potential should use effective contraception during treatment and for 3
             months after the last dose of palbociclib. Animal data suggests that palbociclib may
             affect male fertility.

          -  Prednisone or methylprednisolone for ≤ 120 hours (5 days) may be administered for
             cytoreduction up to 24 hours prior to the start of protocol therapy and as treatment
             for allergic reactions or for physiologic replacement/stress dosing of hydrocortisone
             for documented adrenal insufficiency. Corticosteroids are not allowed for other
             indications. If used to modify immune adverse events related to prior therapy, ≥ 14
             days must have elapsed since last dose of corticosteroid.

          -  Patients who are currently receiving another investigational drug.

          -  Patients who are currently receiving other anti-cancer agents are not eligible [except
             patients receiving hydroxyurea, which may be continued until 24 hours prior to start
             of protocol therapy].

          -  Patients who are currently receiving drugs that are strong inhibitors and/or inducers
             of CYP3A4 or sensitive CYP3A4 substrates and CYP3A4 substrates with a narrow
             therapeutic range are not eligible. Strong inducers or inhibitors of CYP3A4 are
             prohibited from 14 days prior to enrollment to the end of the study.

          -  Patients who are receiving cyclosporine, tacrolimus or other agents to prevent
             graft-versus-host disease post bone marrow transplant.

          -  Patients must be able to swallow intact capsules or liquid. Patients that are unable
             to swallow oral medications may receive palbociclib through an NG tube. G tube
             administration is not allowed.

          -  Patients who have an uncontrolled infection defined as below:

               -  Fever above 38.2°C within 48 hours of study enrollment with clinical signs of
                  infection. Fever that is determined to be due to tumor burden is allowed if
                  patients have documented negative blood cultures for at least 48 hours prior to
                  enrollment and no concurrent signs or symptoms of active infection or hemodynamic
                  instability.

               -  A positive fungal culture within 30 days of study enrollment or active therapy
                  for presumed invasive fungal infection.

               -  Patients may be receiving IV or oral antibiotics to complete a course of therapy
                  for a prior documented infection as long as cultures have been negative for at
                  least 48 hours and signs or symptoms of active infection have resolved. For
                  patients with c. difficile diarrhea, at least 72 hours of antibacterial therapy
                  must have elapsed and stools must have normalized to baseline.

               -  Active viral or protozoal infection requiring IV treatment.

          -  Patients known to have one of the following concomitant genetic syndromes: Down
             syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome,
             Shwachmann syndrome or any other known bone marrow failure syndrome.

          -  Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study.
      

Gender

All

Ages

12 Months - 31 Years

Accepts Healthy Volunteers

No

Contacts

Elizabeth Raetz, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03792256

Organization ID

AINV18P1

Secondary IDs

NCI-2019-02774

Responsible Party

Sponsor

Study Sponsor

Children's Oncology Group


Study Sponsor

Elizabeth Raetz, MD, Study Chair, Children's Oncology Group


Verification Date

June 2021